Assessing the Impact of OBBBA on the Life Sciences Industry

The One Big Beautiful Bill Act (OBBBA), signed into law July 4, will reverberate across the life sciences industry. In addition to creating more flexibility in the orphan drug exception to the Medicare Drug Price Negotiation Program, OBBBA transforms Medicaid eligibility and financing rules that will result in, on average, 8.7 million fewer people covered by Medicaid, based on . Millions more will likely lose coverage beginning in 2026 due to changes to the health insurance Marketplaces. These changes will have profound implications for patient access and direct financial impacts for drug manufacturers, likely increasing the number of uninsured people dependent on manufacturer-funded patient assistance, shifting utilization of the 340B drug pricing program, impacting Medicaid drug rebate obligations, and disrupting the healthcare delivery system across the country. Secondary effects could impact the commercial market.

Join Manatt Health for an interactive webinar unpacking OBBBA’s most consequential provisions for life sciences stakeholders.

Key topics include:

• Effects on patient access, health systems and hospitals, and patient assistance programs from changes to Medicaid eligibility and financing and Marketplace subsidies and eligibility policies.
• Consequences for the 340B drug pricing program, commercial coverage, and Medicaid drug rebates.
• Changes to the orphan drug exemption under the Medicare Drug Price Negotiation Program.

Panelists:

• , Partner, Manatt Health
• , Managing Director, Manatt Health; former deputy administrator, Centers for Medicare & Medicaid Services, and director, Center for Consumer Information and Insurance Oversight
• , Partner, Manatt Health
• , Managing Director, Manatt Health

Date and time:

Wednesday, July 30

1:00 p.m.–2:00 p.m. ET
10:00 a.m.–11:00 a.m. PT